Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

39.31
-0.2900-0.73%
Pre-market: 39.13-0.1800-0.46%08:00 EDT
Volume:5.99M
Turnover:234.62M
Market Cap:45.80B
PE:65.52
High:39.58
Open:39.50
Low:38.52
Close:39.60
52wk High:40.79
52wk Low:18.83
Shares:1.17B
Float Shares:1.09B
Volume Ratio:1.05
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.91
PE(LYR):32.49

Loading ...

Movement Alert|Teva Pharmaceutical Rises 5.07% in Regular Trading, Ordinary Shares Begin Direct Trading on NYSE

Market Focus
·
Sep 15

Teva Pharmaceutical Begins Direct Trading of Shares on NYSE

MT Newswires Live
·
Sep 14

Teva Pharmaceutical Announces Major Senior Notes Financing

TIPRANKS
·
Sep 12

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

GlobeNewswire
·
Sep 10

Teva Pharmaceuticals Price Target Announced at $45.00/Share by Leerink Partners

Dow Jones
·
Sep 09

Leerink Partners Initiates Coverage on Teva Pharmaceutical Industries With Outperform Rating, $45 Price Target

MT Newswires Live
·
Sep 09

Teva initiated with an Outperform at Leerink

TIPRANKS
·
Sep 09

Teva Pharmaceuticals : UBS Raises Target Price to $48 from $42

THOMSON REUTERS
·
Sep 07

Teva Announces Launch of Offering of Senior Notes

THOMSON REUTERS
·
Sep 07

Teva Pharmaceuticals is Maintained at Buy by UBS

Dow Jones
·
Sep 05

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

TIPRANKS
·
Sep 03

J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential

TIPRANKS
·
Sep 03

Teva Upgraded to Buy on Strengthening Autoimmune Pipeline and Validating Celiac Disease Data

TIPRANKS
·
Sep 03

US-Listed Shares of Teva Pharmaceutical up 3.5% Premarket After Co's Immune Disorder Drug Meets Main Goal in Mid-Stage Trial

THOMSON REUTERS
·
Sep 02

Teva's Stock Jumps over 3% as Immune Disorder Drug Meets Main Goal in Mid-Stage Trial

Reuters
·
Sep 02

Movement Alert|Teva Pharmaceutical Rises 5.11% in Pre-Market Trading, Positive Phase 2a Data for Anti-IL-15 Drug TEV-408 in Celiac Disease

Market Focus
·
Sep 02

Teva Pharmaceutical Reports Positive Topline Data for Anti-IL-15 Drug in Celiac Disease

MT Newswires Live
·
Sep 02

Teva: Tev '408 was Well-Tolerated with no Safety Signals Observed to Date

THOMSON REUTERS
·
Sep 02

Teva - Tev ‘408 Demonstrates Statistically Significant Prevention of Gluten-Induced Damage in Phase 2a Study

THOMSON REUTERS
·
Sep 02

Teva - Phase 2a Study Meets Primary Endpoint with Significant Prevention of Gluten-Induced Damage

THOMSON REUTERS
·
Sep 02